Patients and methods the two patients included in this case report were diagnosed with B-precursor aLL at St. Jude Children's research hospital and were treated with a common regimen. Both patients developed hypersensitivity reactions to PEGylated E. coli asparaginase and Erwinia asparaginase early in treatment, and they were challenged with native E. coli asparaginase. Serum samples were collected for estimating the pharmacokinetic parameters of each patient during native E. coli asparaginase therapy. Results Challenges with native E. coli asparaginase were successful, and asparaginase serum concentrations above therapeutic levels were attained in both patients. Conclusions these two cases suggest that some patients can be given native E. coli asparaginase after hypersensitivity reactions to PEGylated asparaginase and achieve therapeutic concentrations of the drug in serum.
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particular manufacturer of the preparation. Oncaspar is a PEGylated form of the native Escherichia coli asparaginase that has a half-life of about a week, whereas the native E. coli asparaginase (Elspar) and Erwinia asparaginase (Erwinase) have a half-life of 1.3 and 0.65 days, respectively [1, 4, 5] . asparaginase-induced hypersensitivity reactions can decrease exposure to asparaginase. hypersensitivity reactions to asparaginase can be as frequent as 63 %, and patients with reactions to asparaginase have been reported to have faster drug clearances compared to patients that did not have reactions [6, 7] . Furthermore, patients that develop neutralizing antibodies to asparaginase, even in the absence of a clinical reaction, may have sub-therapeutic serum concentrations due to an accelerated asparaginase clearance [1, 2, 8] . neutralizing antibodies generated against the native E. coli preparation have been shown to cross-react with Oncaspar asparaginase but not with Erwinase asparaginase [9] .
Patients with low asparaginase exposure due to toxicities have been reported to have worse outcomes [10] . therefore, substituting a different preparation of asparaginase after a hypersensitivity reaction or after the detection of neutralizing antibodies can extend asparaginase therapy and possibly improve patient outcome. In clinical trials, PEGylated asparaginase has been associated with a decreased frequency of hypersensitivity [10] , and Oncaspar is approved for use in patients who develop allergies to native E. coli asparaginase. Erwinia asparaginase is generally the first choice to use in patients who react to primary treatment with Oncaspar, but some of these patients subsequently develop allergies to Erwinia asparaginase. It is unknown whether patients with past hypersensitivity reactions to Oncaspar asparaginase will cross-react to Elspar asparaginase. herein, we report successful challenges using Elspar in two pediatric aLL patients with previous hypersensitivity reactions to both Oncaspar and Erwinase preparations of asparaginase. asparaginase serum concentrations above therapeutic levels were attained in both patients, a finding suggesting that selected patients with Oncaspar hypersensitivities may continue asparaginase therapy with Elspar asparaginase without cross-reactivity.
Case reports
the two patients included in this case report were diagnosed with B-precursor aLL at St. Jude Children's research hospital. Patient a was enrolled on the total XVI acute leukemia protocol [11] , and Patient B was not enrolled on a clinical trial but did provide consent for similar treatment regimen and asparaginase serum measures. table 1 summarizes the pertinent characteristics of the two patients. Oncaspar (3,000 Iu/m 2 , IV) was given at day 3 of remission induction in both patients.
Patient a tolerated the first dose of Oncaspar during induction but reacted to the second dose of Oncaspar given during week 1 of continuation ( Fig. 1a . the symptoms of the grade 4 reaction included anaphylaxis, rash, and shortness of breath. he was then treated with Erwinase (20,000 Iu/m 2 per dose) thrice weekly for six doses during remission induction. he developed a hypersensitivity reaction to Erwinase when it was resumed at week 1 of continuation treatment (Fig. 1b) . the symptoms included urticaria, bronchospasm, and shortness of breath. he was then rechallenged with intramuscular Elspar (12,500 Iu/ m 2 per dose) twice weekly with diphenhydramine (25 mg, PO) and ranitidine (100 mg, PO) premedication 1 h before each Elspar administration from week 3 to week 13 of continuation treatment. Elspar was discontinued after 16 doses were given due to extensive venous thrombosis and associated superior vena cava (SVC) syndrome (Supplemental  table 1 ).
Antibody testing
a total of 19 serum samples were collected from Patient a from induction through continuation treatment for antibody testing (table 2) . the antibody levels in samples were determined by ELISa as described previously [12] . two additional antigens [polyethylene glycol (PEG)-superoxide dismutase and PEG-catalase] were included in the assay for the detection of anti-PEG antibodies. none of the samples collected for Patient a tested positive for IgG, Igm, or IgE antibodies against asparaginase (Elspar, Erwinia, and Oncaspar) or PEG. Furthermore, serum samples collected 2 h after the first Elspar dose were tested for elevated tryptase levels by aruP Laboratories (Salt Lake City, ut). the samples were within the normal concentration range of (4) negative (4) negative (4) negative (4) negative (4) negative (4) 2-40 days (6) 0.08-2.20 a Patient B
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negative (20) negative (20) negative (20) negative (20) negative (20) negative (20) 1-21 days (20) 0.01-1.10 e tryptase, consistent with the absence of a hypersensitivity reaction during the Elspar challenge [13] . Patient B had two serum samples collected during induction immediately following the hypersensitivity reaction (1.6 and 3.5 h after Oncaspar administration). the samples were tested for IgG, Igm, or IgE antibodies against asparaginase (Elspar, Erwinia, and Oncaspar) and PEG. the patient did not have any detectable levels of anti-asparaginase antibodies, but anti-PEG IgG antibodies were detected (table 2) . no other samples collected for this patient throughout all phases of treatment tested positive for any antibody including anti-PEG antibodies (table 2) . nevertheless, it is possible that a previous exposure and sensitization to PEG may have played a role in the hypersensitivity reaction and antibody response to Oncaspar [14] . tryptase levels were not measured for Patient B.
Because IgE antibodies may have been bound to mast cells and because its presence in serum can be fleeting, it is possible that IgE was formed in these patients but not detected in the samples we assayed.
Asparaginase activity
Samples from Patient a were collected during induction for asparaginase activity testing, and all samples collected within 2 weeks of the Oncaspar dose were above 0.1 Iu/ mL (table 2). Patient B did not receive a full dose of Oncaspar due to the hypersensitivity reaction, and therefore, it is not surprising that the asparaginase activity measured from samples collected during induction were below therapeutic concentrations (table 2). Only Patient B had a single sample available for asparaginase activity quantification during Erwinase treatment (table 2), and activity was >0.1 Iu/mL. asparaginase activity was determined in several serum samples collected throughout Elspar asparaginase exposure in both patients ( Fig. 2; table 2 ). asparaginase drug concentrations were modeled using a one-compartment pharmacokinetic model with first-order absorption and michaelis-menten elimination [12] . the pharmacokinetic parameters for each patient during Elspar therapy were estimated using nOnmEm (version 7.2) [15] . asparaginase concentrations were above the 0.1 Iu/mL threshold in all samples collected within 1 week of a dose for both patients ( Fig. 2; table 2 ). the clearance was higher, and half-life was shorter for both Patients a and B than were reported for newly diagnosed aLL patients given Elspar, but the treatment doses were high enough to maintain serum asparaginase activity above 0.1 Iu/mL ( Fig. 2; Supplemental  table 2 ). no CSF asparagine data are available for either patient during Elspar therapy to evaluate the pharmacodynamics effect of Elspar asparaginase.
Discussion
Successful asparaginase substitutions require that there be no or little cross-reactivity with the offending preparations in regard to clinical reactions and to the neutralization of asparaginase activity. Pretreatment with steroids and antihistamines may mitigate hypersensitivity reactions, but this strategy is not suitable unless neutralizing antibodies are also diminished by pretreatment medication. therefore, not only is it important for asparaginase treatment strategies to mitigate the severity of the hypersensitivity reaction, but strategies are also required to maintain efficacious concentrations of asparaginase.
Previously, our practice was to discontinue asparaginase treatment if hypersensitivity reactions occur to both Oncaspar and Erwinia asparaginase. however, due to a lack of detection of antibodies to Elspar or Oncaspar, there was no indication that the mediator responsible for the previous reactions would cross-react to Elspar asparaginase. Based on this limited information and due to the early stage in treatment that the patients developed their hypersensitivity reactions, putting them at a higher risk of poor outcome due to low asparaginase exposure [10] , we decided to challenge these two patients with Elspar asparaginase.
Elspar challenges were successful in both of these patients after their previous hypersensitivities to other preparations of asparaginase. although the absence of tryptase in Patient a and the lack of any asparaginase-specific antibodies in all samples tested are consistent with a lack of an immediate hypersensitivity reaction having occurred (as opposed to the pretreatment medications masking the hypersensitivity reaction), the possibility that these patients had hypersensitivity reactions cannot be ruled out. the patients were able to tolerate multiple doses of Elspar, although both eventually had asparaginase discontinued due to other asparaginase-related toxicities. nevertheless, the Elspar substitutions were able to extend therapy for several weeks, and samples collected during Elspar therapy displayed asparaginase drug concentrations above the minimal threshold required for asparagine depletion [3] .
Even though antibodies were not detected in either patient during Elspar therapy, the clearance estimates were higher in both patients compared to de novo patients (Supplemental table 2) [1, [16] [17] [18] [19] . the pharmacokinetic parameters estimated were more similar to those reported from pediatric patients with relapsed aLL receiving Elspar and negative for anti-asparaginase IgG antibodies (clearance range: 1,768-6,865 mL/day/m 2 ) than to newly diagnosed aLL patients [12] . Our results suggest that patients with previous allergies to Oncaspar may require higher doses of Elspar asparaginase to achieve serum concentrations comparable to those of non-allergic, de novo patients receiving Elspar.
the mechanism responsible for asparaginase-induced hypersensitivity is unknown. although studies have demonstrated a relationship between Elspar-specific IgG antibodies and reactions to Elspar [20] , there are fewer data on the mechanisms of reaction to Oncaspar. the cases presented here are the first to show successful challenge with native E. coli asparaginase (Elspar) after hypersensitivity reactions to Oncaspar, and they support a hypothesis that the mediators of hypersensitivity responsible for Oncaspar allergies may not necessarily cross-react with Elspar asparaginase. these results, based on the two patients included in this case report, suggest that it may be possible to treat patients with Elspar asparaginase after hypersensitivity reactions to Oncaspar asparaginase if there is no evidence of anti-Elspar antibodies, and that Elspar in such patients can achieve therapeutic drug concentrations in serum.
